![John Sørensen Haurum](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Sørensen Haurum
Director Ejecutivo en F-star Alpha Ltd. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
David Colin Conway Llewellyn | M | 37 |
DJS Antibodies Ltd.
![]() DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | - |
Henrik Stage | M | - |
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | - |
Tolga Hassan | M | 53 |
F-Star Beta Ltd.
![]() F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom.
F-star Alpha Ltd.
![]() F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | 8 años |
Paolo Michieli | M | - |
AgomAb Therapeutics NV
![]() AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | 7 años |
Joseph James Illingworth | M | 36 |
DJS Antibodies Ltd.
![]() DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | - |
Helmut Schühsler | M | 65 |
F-Star Beta Ltd.
![]() F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom.
F-star Alpha Ltd.
![]() F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | 10 años |
John Blodgett Edwards | M | - |
F-Star Beta Ltd.
![]() F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom.
F-star Alpha Ltd.
![]() F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | 10 años |
Christoffer Nielsen | M | - |
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | - |
Robert James | M | 59 |
NeoPhore Ltd.
![]() NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom. | - |
Eliot Forster | M | 58 |
F-Star Beta Ltd.
![]() F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom.
F-star Alpha Ltd.
![]() F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | - |
Deborah Harland | M | 64 |
F-Star Beta Ltd.
![]() F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom.
F-star Alpha Ltd.
![]() F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | 10 años |
Jean-Francois Formela | M | 67 |
F-Star Beta Ltd.
![]() F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom.
F-star Alpha Ltd.
![]() F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | 10 años |
Anne Burger | F | - |
CatalYm GmbH
![]() CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | - |
Tim Knotnerus | M | - |
AgomAb Therapeutics NV
![]() AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | 5 años |
Florian Ruker | M | 67 |
F-Star Beta Ltd.
![]() F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom. | 10 años |
CARL KILANDER | M | - |
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | - |
Clare Elizabeth Terlouw | F | 51 |
DJS Antibodies Ltd.
![]() DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | - |
Ohad Hammer | M | - |
AgomAb Therapeutics NV
![]() AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | - |
Halse Rez | M | - |
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | - |
Lars H. Engelholm | M | - |
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | - |
Sanne de Jongh | F | - |
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | - |
Matthew Baker | M | 53 |
NeoPhore Ltd.
![]() NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom. | 4 años |
Pieter Jeroen Bakker | M | - |
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | - |
Michael Pehl | M | 60 |
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | 3 años |
Neil Brewis | M | 57 |
F-star Alpha Ltd.
![]() F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | 9 años |
Pietro Puglisi | M | - |
NeoPhore Ltd.
![]() NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom. | 3 años |
Hans van Eenennaam | M | - |
CatalYm GmbH
![]() CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | - |
Hiromichi Kimura | M | 73 |
NeoPhore Ltd.
![]() NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom. | - |
Michael Lee | M | 45 |
AgomAb Therapeutics NV
![]() AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | - |
Phil L'Huillier | M | - |
CatalYm GmbH
![]() CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | 3 años |
Heikki Lanckriet | M | 46 |
NeoPhore Ltd.
![]() NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom. | - |
Graeme Martin | M | - |
DJS Antibodies Ltd.
![]() DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | 6 años |
Joël Jean-Mairet | M | 52 |
ADCendo ApS
![]() ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | - |
Mads Laustsen | M | 67 |
Synklino ApS
![]() Synklino ApS Medical/Nursing ServicesHealth Services Synklino ApS is a Danish biotech company that focuses on developing innovative therapies against virus infections. The company's first-in-class drug candidate, Syn002, targets cytomegalovirus infection in transplantation patients and aims to change the current antiviral treatment paradigm. Synklino is owned by renowned Nordic funds and institutional investors, including Eir Ventures, the Danish Growth Fund, and PKA, as well as approximately 70 private shareholders. The company is a spinout from the University of Copenhagen and the Technical University of Denmark and is incubated at the BioInnovation Institute in its prestigious Creation House program. | 6 años |
Richard Shen | M | 43 |
DJS Antibodies Ltd.
![]() DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Holger N. Reithinger | M | 58 |
CatalYm GmbH
![]() CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | 5 años |
Christine Cvijic | F | 46 |
ImClone LLC
![]() ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 3 años |
Gregory D. Plowman | M | - |
ImClone LLC
![]() ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | - |
Nessan Bermingham | M | 51 |
F-Star Beta Ltd.
![]() F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom. | 1 años |
Patrick Johan Hendrik Krol | M | 60 |
F-Star Beta Ltd.
![]() F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom. | 5 años |
Gregory Mayes | M | 55 |
ImClone LLC
![]() ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 6 años |
Joseph I. DePinto | M | 57 |
ImClone LLC
![]() ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 2 años |
Christopher Torrance | M | - |
NeoPhore Ltd.
![]() NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom. | - |
Ramona M. Lloyd | M | - |
ImClone LLC
![]() ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 1 años |
Elizabeth Yamashita | F | - |
ImClone LLC
![]() ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 5 años |
Glenn Whaley | M | 56 |
ImClone LLC
![]() ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | 6 años |
Johannes Zanzinger | M | - |
AgomAb Therapeutics NV
![]() AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Reino Unido | 21 | 44.68% |
Dinamarca | 10 | 21.28% |
Estados Unidos | 7 | 14.89% |
Bélgica | 5 | 10.64% |
Alemania | 4 | 8.51% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- John Sørensen Haurum
- Red Personal